Laboratory compound comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-11-14. Where a claim depends on a specific study, the study is described rather than over-claimed.
Legal status varies by country. In some places, cardarine is controlled under medicines or psychoactive substances laws; in others, it may be sold with minimal oversight as a research chemical. Customs agencies have intercepted shipments, and several national health agencies have issued warnings about products marketed for bodybuilding or performance enhancement. The lack of a standardized pharmaceutical supply means identity, purity, and contamination levels can differ widely between samples. These factors make cardarine a regulatory and public health concern rather than a conventional prescription drug.
Cardarine is a common name for GW501516, a synthetic compound first described in the 1990s as a selective agonist of the peroxisome proliferator-activated receptor delta. It was studied in preclinical models for metabolic and cardiovascular conditions, but it has not been approved as a medicine in the United States, Europe, or other major jurisdictions. Retail products labeled as cardarine are generally research chemicals or supplements, not pharmaceutical formulations. Because human safety and efficacy data remain limited, regulatory agencies treat it as an unapproved substance rather than a therapeutic product.
A persistent misconception is that cardarine is a fat-burning drug or a safe alternative to anabolic steroids. No approved therapeutic product exists, and human safety data are limited. The tumor findings in rodents remain a central concern in scientific reviews. Products sold online may contain inaccurate labels, impurities, or different compounds entirely, which complicates any assessment of effects. Independent testing of such products has reported frequent mislabeling. For these reasons, discussions in the literature emphasize risks and unknowns rather than benefits.
Cardarine is not approved for human therapeutic use in any major jurisdiction. It appears on the World Anti-Doping Agency Prohibited List as a PPARδ agonist within the hormone and metabolic modulators category. Sports organizations test for it because it has been detected in athlete samples and seized products. Regulatory actions against marketed research chemical versions have occurred in several countries, though enforcement varies. Availability through unregulated channels complicates oversight.
Analytical laboratories typically identify cardarine and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is a common matrix in anti-doping testing, while blood and tissue may be used in research settings. Detection windows depend on the assay, the sample matrix, and the compound's metabolism. Because cardarine is extensively metabolized, laboratories often target specific metabolites to improve sensitivity and confirmation. Reference standards are required for reliable quantification. Method validation includes checks for selectivity, linearity, and carryover.
| Property | Value | Notes |
|---|---|---|
| IUPAC name | {4-[({4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl}methyl)sulfanyl]phenoxy}acetic acid | Systematic name for GW501516 |
| CAS Registry Number | 317318-70-0 | Unique identifier for the parent compound |
| Molecular formula | C21H18F3NO3S2 | Includes carbon, hydrogen, fluorine, nitrogen, oxygen, and sulfur |
| Molecular weight | 453.5 g/mol | Approximate value for the neutral form |
| Appearance | White to off-white powder | Typical description for purified laboratory material |
GW501516 acts on PPARδ, a nuclear receptor that helps regulate fatty acid oxidation and energy homeostasis. In animal studies, activation of this receptor was associated with increased endurance and changes in lipid metabolism. Human trials examined effects on blood lipids and other metabolic markers, but the compound did not advance to approval. Rodent studies later reported tumors in multiple tissues at doses used in those experiments. Whether those findings translate to human risk remains uncertain, and the clinical relevance of the animal data is still debated.
Regulatory bodies treat GW501516 as a prohibited substance in competitive sport. The World Anti-Doping Agency added it to the prohibited list, and it falls under classes covering metabolic modulators and hormone-related agents. It is not approved by drug regulators for human use, and it is not a lawful dietary supplement. Products sold under the cardarine name may contain unlisted ingredients or different compounds. Because no approved product exists, quality and identity are not guaranteed by pharmaceutical manufacturing standards.
Cardarine is a common name for the investigational chemical GW501516, also written GW-1516. It was developed as a peroxisome proliferator-activated receptor delta agonist for metabolic conditions such as dyslipidemia. Early research focused on lipid handling and energy use in skeletal muscle and other tissues. The compound was never approved as a medicine. In public discussion, it is often grouped with performance-enhancing substances, although its receptor target differs from that of anabolic steroids or selective androgen receptor modulators. Regulatory and health authorities have issued warnings about its use.
The compound is typically described as a laboratory compound rather than a therapeutic product. Published reports have explored its role in lipid disorders, insulin sensitivity, and exercise metabolism, yet no major drug regulator has approved it for medical use. Commercial samples sold under the cardarine name may vary in purity and identity. Analytical confirmation is therefore necessary when the material is discussed in scientific or regulatory contexts. Its classification as a prohibited substance in sport further shapes how it is studied and reported.
Cardarine is a common name for GW501516, a synthetic compound studied for its effects on lipid and glucose metabolism. It functions as an agonist at peroxisome proliferator-activated receptor delta, or PPARδ, a nuclear receptor that influences gene expression. The molecule is not a steroid, nor is it a selective androgen receptor modulator. It is also known in research and sports literature as GW-501516 and endurobol. Early laboratory work examined its metabolic activity in cell cultures and animal models.
== Treatment == Management of acanthosis nigricans (AN) generally involves evaluating for and addressing any associated underlying condition rather than treating the skin changes alone. When AN occurs in the setting of obesity, insulin resistance or type 2 diabetes mellitus, improvement in metabolic status may be followed by gradual softening or lightening of the lesions, although the degree of change varies. Drug-induced AN may improve after reduction or discontinuation of the causative medication when clinically appropriate. Reported associations include systemic corticosteroids, high-dose nicotinic acid and certain hormonal therapies. In malignancy-associated AN, particularly that linked to gastrointestinal adenocarcinomas, regression of the cutaneous changes has been observed following treatment of the underlying tumour, though this is not universal. Sudden onset, rapid progression or mucosal involvement have been described in malignant forms and may prompt further evaluation.
=== Steroid hormone activity === The effects of testosterone in humans and other vertebrates occur by way of multiple mechanisms: by activation of the androgen receptor (directly or as dihydrotestosterone), and by conversion to estradiol and activation of certain estrogen receptors. Androgens such as testosterone have also been found to bind to and activate membrane androgen receptors. Free testosterone (T) is transported into the cytoplasm of target tissue cells, where it can bind to the androgen receptor, or can be reduced to 5α-dihydrotestosterone (5α-DHT) by the cytoplasmic enzyme 5α-reductase. 5α-DHT binds to the same androgen receptor even more strongly than testosterone, so that its androgenic potency is about 5 times that of T. The T-receptor or DHT-receptor complex undergoes a structural change that allows it to move into the cell nucleus and bind directly to specific nucleotide sequences of the chromosomal DNA. The areas of binding are called hormone response elements (HREs), and influence transcriptional activity of certain genes, producing the androgen effects. Androgen receptors occur in many different vertebrate body system tissues, and both males and females respond similarly to similar levels. Greatly differing amounts of testosterone prenatally, at puberty, and throughout life account for a share of biological differences between males and females. The bones and the brain are two important tissues in humans where the primary effect of testosterone is by way of aromatization to estradiol.
Drug developers have focused on selective COX-2 inhibition, particularly as a way to minimize the gastrointestinal side effects of nonsteroidal anti-inflammatory drugs. However, the cardiovascular adverse effects of some COX-2 inhibitors has led to lawsuits alleging wrongful death by heart attack. Yet, other significantly COX-selective nonsteroidal anti-inflammatory drugs, such as diclofenac, have been well tolerated by most of the population. Besides the COX-inhibition, several other molecular targets of diclofenac possibly contributing to its pain-relieving actions have recently been identified. These include:
=== Immune compromise === The immune response is impaired in individuals with diabetes mellitus. Cellular studies have shown that hyperglycemia both reduces the function of immune cells and increases inflammation.
== External links == International Chemical Safety Card 0950. NIOSH Pocket Guide to Chemical Hazards. R., Frances (2006). "Is there poison in auto air bags?". The Straight Dope. Archived from the original on 2020-07-31. Retrieved 2022-10-25.
Sources: en.wikipedia.org
The press over the litigation and public concern over the claims of A2 Corporation led the New Zealand Food Safety Authority and the Ministry of Health and the Food Standards Australia New Zealand to issue statements confirming the safety of conventional milk. A2 Corporation was able to obtain agreements with enough dairy farmers to launch A1 protein-free milk under its a2 and a2 MILK brands in New Zealand at the end of April 2003. In the middle of 2003, both founders of the company died. In July, Paterson was found dead in his hotel room during a business trip at the age of 50, and a month later Dr Corran McLachlan died of cancer at the age of 59. In New Zealand it is illegal to make health claims about a food product without providing scientific evidence and registering the food as a medicine, and in November 2003 the New Zealand Commerce Commission advised that A2 Corporation Ltd and its licensed producers of A1 protein-free milk had agreed to amend the health claims in their promotional material following a warning from the commission. By end of 2003 the weakened A2 Corporation had withdrawn the litigation against Fonterra and negotiations had resumed. The company, which had been in a tenuous financial situation since beginning trading in May, went into administration in October and was liquidated in November, owing farmers and processors tens of thousands of dollars. A NZ$1.27 million federal government grant awarded to the company in August as part of the Regional Partnerships Program was also cancelled.
=== Industrial chemicals === Industrial chemicals from various industries produce harmful chemicals that are known to cause harm to human health and the environment. Common industrial chemicals, like 1,4-Dioxanes, Perfluorooctane sulfonate (PFOS) and Perfluorooctanoic acid (PFOA), are commonly found in various water sources.
== Management == Secondary Raynaud's is managed primarily by treating the underlying cause, and as with primary Raynaud's, by avoiding triggers, such as cold, emotional and environmental stress, vibrations, and repetitive motions, and avoiding smoking (including passive smoking) and sympathomimetic drugs.
The free flow of ions between cells enables rapid non-chemical-mediated transmission. Rectifying channels ensure that action potentials move only in one direction through an electrical synapse. Electrical synapses are found in all nervous systems, including the human brain, although they are a distinct minority.
Sources: en.wikipedia.org
SIMS and FAB are quite similar. SIMS uses an ion beam, usually Ar+ or Cs+. FAB uses a neutral atom beam, usually Ar or Xe. For SIMS and FAB, if the matrix compound is more acidic than the analyte, then predominantly (M + H)+ forms formed, and conversely (M − H)−. Also possibly forming (M + Na)+, (M + K)+, etc, if the matrix is contaminated incidentally (adventitiously) by sodium, potassium, etc. Typical matrix materials include glycerol, thioglycerol, 3-nitrobenzyl alcohol, diethanolamine, triethanolamine, and dithiothreitol-dithioerythritol mixture. They are usually used to analyze polypeptides and oligonucleotides up to 20 kDa. MALDE uses a photon beam, usually the soft-UV 337 nm nitrogen laser. It can also use an infrared (IR) laser for direct analysis of samples contained in gels or thin-layer chromatography (TLC) plates. MALDE can analyze small polymers (~1 kDa), to oligosaccharides, oligonucleotides and polypeptides, antibodies, up to small proteins (~300 kDa). It is highly sensitive, requiring only femtomoles of sample. Desorption/ionization on silicon (DIOS) is similar to MALDE, but without the matrix. The sample is deposited directly on a nanostructured (porous silicon) surface and the sample desorbed directly from the nanostructured surface through the adsorption of laser light energy. DIOS has been used to analyze organic molecules, metabolites, biomolecules and peptides, and, ultimately, to image tissues and cells.
Cuprate of Tl–Ba–Ca The first series of the Tl-based superconductor containing one Tl–O layer has the general formula TlBa2Can−1CunO2n+3, whereas the second series containing two Tl–O layers has a formula of Tl2Ba2Can−1CunO2n+4 with n =1, 2 and 3. In the structure of Tl2Ba2CuO6 (Tl-2201), there is one CuO2 layer with the stacking sequence (Tl–O) (Tl–O) (Ba–O) (Cu–O) (Ba–O) (Tl–O) (Tl–O). In Tl2Ba2CaCu2O8 (Tl-2212), there are two Cu–O layers with a Ca layer in between. Similar to the Tl2Ba2CuO6 structure, Tl–O layers are present outside the Ba–O layers. In Tl2Ba2Ca2Cu3O10 (Tl-2223), there are three CuO2 layers enclosing Ca layers between each of these. In Tl-based superconductors, Tc is found to increase with the increase in CuO2 layers. However, the value of Tc decreases after four CuO2 layers in TlBa2Can−1CunO2n+3, and in the Tl2Ba2Can−1CunO2n+4 compound, it decreases after three CuO2 layers. Cuprate of Hg–Ba–Ca The crystal structure of HgBa2CuO4 (Hg-1201), HgBa2CaCu2O6 (Hg-1212) and HgBa2Ca2Cu3O8 (Hg-1223) is similar to that of Tl-1201, Tl-1212 and Tl-1223, with Hg in place of Tl. It is noteworthy that the Tc of the Hg compound (Hg-1201) containing one CuO2 layer is much larger as compared to the one-CuO2-layer compound of thallium (Tl-1201). In the Hg-based superconductor, Tc is also found to increase as the CuO2 layer increases. For Hg-1201, Hg-1212 and Hg-1223, the values of Tc are 94, 128, and the record value at ambient pressure 134 K (−139 °C), respectively, as shown in table below.
== Assessing beta cell function == Measuring beta-cell function is a challenge, since insulin secretory capacity cannot be readily assessed. Therefore, indirect methods of measurement have been developed. They include dynamic and static function tests.
==== Myelopathy ==== Copper deficiency myelopathy in humans was discovered and first described by Schleper and Stuerenburg in 2001. They described a patient with a history of gastrectomy and partial colonic resection who presented with severe tetraparesis and painful paraesthesias and who was found on imaging to have dorsomedial cervical cord T2 hyperintensity. Upon further analysis, it was found that the patient had decreased levels of serum coeruloplasmin, serum copper, and CSF copper. The patient was treated with parenteral copper and the patient's paraesthesias did resolve. Since this discovery, awareness of copper-deficiency myelopathy and its treatment has increased. Patients typically present difficulty walking (gait difficulty) caused by sensory ataxia (irregular muscle coordination) due to dorsal column dysfunction or degeneration of the spinal cord (myelopathy). Patients with ataxic gait have problems balancing and display an unstable wide walk. They often feel tremors in their torso, causing sideways jerks and lunges. In brain MRI, there is often an increased T2 signalling at the posterior columns of the spinal cord in patients with myelopathy caused by copper deficiency. T2 signalling is often an indicator of neurodegeneration. There are some changes in the spinal cord MRI involving the thoracic cord, the cervical cord, or sometimes both. Copper deficiency myelopathy is often compared to subacute combined degeneration (SCD).
=== Bible verses === In-N-Out prints Bible citations in small print on areas of packaging (such as "John 3:16", "Proverbs 3:5", "Proverbs 24:16", "Nahum 1:7", "Luke 6:35" and "Revelation 3:20"). They are primarily found on the bottom underside of drink cups and the wrappers that hold their burgers together. This practice began in the 1980s during Rich Snyder's presidency, a reflection of the evangelical Christian beliefs held by the Snyder family.
Sources: en.wikipedia.org
No. Major drug regulators have not approved GW501516 for treating any medical condition. Products sold as cardarine are typically unapproved research chemicals or supplements, so their contents and safety are not assured.
It is prohibited by the World Anti-Doping Agency as a hormone and metabolic modulator. Athletes who test positive for GW501516 can face sanctions, including suspensions and loss of results.
Cardarine is a common or trade-style name, while GW501516 is the research code for the same chemical entity. Some sources also use Endurobol or GSK-516. The names refer to the same compound, not distinct drugs.
No. Cardarine has not received approval for human therapeutic use in major jurisdictions. It remains an investigational compound.